TGFβ1 signaling via αVβ6 integrin

Molecular Cancer

Volumn 2, Issue , 2003, Pages

  Kracklauer, Martin P ^a   Schmidt, Christian ^b   Sclabas, Guido M ^b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cytoskeleton; Growth inhibition; Integrin; Signaling; TGF 1

Indexed keywords

ALPHA5 INTEGRIN; BETA6 INTEGRIN; PROTEIN P21; PROTEIN P27; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALPHAVBETA6 INTEGRIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; FIBRONECTIN; FLAVONOID; INTEGRIN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN; SMAD3 PROTEIN, HUMAN; SMAD4 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TYROSINE;

AMINO ACID SEQUENCE; CARCINOMA CELL; CELL FRACTIONATION; CELL GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING; ARTICLE; CELL DIVISION; CELL LINE; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CYTOSKELETON; DRUG ANTAGONISM; DRUG EFFECT; HELA CELL; METABOLISM; PHOSPHORYLATION; RETRACTED ARTICLE; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE; CELL LINE, TUMOR; CYTOSKELETON; DNA-BINDING PROTEINS; FIBRONECTINS; FLAVONOIDS; HELA CELLS; HUMANS; INTEGRINS; MICROSCOPY, CONFOCAL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TYROSINE;

EID: 2942589083     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-2-28     Document Type: Review

References (125)

1. Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
2. Massague J, Blain SW and Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
3. Massague J: TGFbeta signaling: receptors, transducers, and Mad proteins. Cell 1996, 85:947-950.
4. Massague J: Receptors for the TGF-beta family. Cell 1992, 69:1067-1070.
5. Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R and Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 1987, 48:409-415.
6. Fink SP, Mikkola D, Willson JK and Markowitz S: TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003, 22:1317-1323.
7. Feng XH, Liang YY, Liang M, Zhai W and Lin X: Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell 2002, 9:133-143.
8. Feng XH, Lin X and Derynck R: Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. Embo J 2000, 19:5178-5193.
9. Stopa M, Anhuf D, Terstegen L, Gatsios P, Gressner AM and Dooley S: Participation of Smad2, Smad3, and Smad4 in transforming growth factor beta (TGF-beta)-induced activation of Smad7. THE TGF-beta response element of the promoter requires functional Smad binding element and E-box sequences for transcriptional regulation. J Biol Chem 2000, 275:29308-29317.
10. Labbe E, Silvestri C, Hoodless PA, Wrana JL and Attisano L: Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 1998, 2:109-120.
11. Goto D, Yagi K, Inoue H, Iwamoto I, Kawabata M, Miyazono K and Kato M: A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3, and has a dominant negative effect on TGF-beta signals. FEBS Lett 1998, 430:201-204.
12. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K and ten Dijke P: TGFbeta receptor-mediated signalling through Smad2, Smad3 and Smad4. Embo J 1997, 16:5353-5362.
13. Song CZ, Siok TE and Gelehrter TD: Smad4/DPC4 and Smad3 mediate transforming growth factor-beta (TGF-beta) signaling through direct binding to a novel TGF-beta-responsive element in the human plasminogen activator inhibitor-1 promoter. J Biol Chem 1998, 273:29287-29290.
14. Feng XH, Zhang Y, Wu RY and Derynck R: The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 1998, 12:2153-2163.
15. Lagna G, Hata A, Hemmati-Brivanlou A and Massague J: Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 1996, 383:832-836.
16. Yang X, Li C, Xu X and Deng C: The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A 1998, 95:3667-3672.
17. Cutry AF, Kinniburgh AJ, Twardzik DR and Wenner CE: Transforming growth factor alpha (TGF alpha) induction of C-FOS and C-MYC expression in C3H 10T1/2 cells. Biochem Biophys Res Commun 1988, 152:216-222.
18. Mercier T, Gaillard-Sanchez I, Martel P and Seillan-Heberden C: Constitutive overexpression of c-fos protein in rat liver epithelial cells decreases TGF-beta synthesis and increases TGF-beta 1 receptors. Biochim Biophys Acta 1995, 1266:64-72.
19. Zhang Y, Feng XH and Derynck R: Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998, 394:909-913.
20. Kutz SM, Providence KM and Higgins PJ: Antisense targeting of c-fos transcripts inhibits serum- and TGF-beta 1-stimulated PAI-1 gene expression and directed motility in renal epithelial cells. Cell Motil Cytoskeleton 2001, 48:163-174.
21. Chen CR, Kang Y, Siegel PM and Massague J: E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 2002, 110:19-32.
22. Kowalik TF: Smad about E2F. TGFbeta repression of c-Myc via a Smad3/E2F/p107 complex. Mol Cell 2002, 10:7-8.
23. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M and Massague J: TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 2001, 3:400-408.
24. Yang L, Yang J, Venkateswarlu S, Ko T and Brattain MG: Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 2001, 188:383-393.
25. Badiavas EV, Zhou L and Falanga V: Growth inhibition of primary keratinocytes following transduction with a novel TGFbeta-1 containing retrovirus. J Dermatol Sci 2001, 27:1-6.
26. Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W, Kalthoff H and Naumann M: TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 1999, 14:93-101.
27. Moskaluk CA and Kern SE: Cancer gets Mad: DPC4 and other TGFbeta pathway genes in human cancer. Biochim Biophys Acta 1996, 1288:M31-3.
28. Chen C, Wang XF and Sun L: Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem 1997, 272:12862-12867.
29. Frey RS and Mulder KM: TGFbeta regulation of mitogen-activated protein kinases in human breast cancer cells. Cancer Lett 1997, 117:41-50.
30. Simeone DM, Pham T and Logsdon CD: Disruption of TGFbeta signaling pathways in human pancreatic cancer cells. Ann Surg 2000, 232:73-80.
31. Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T and Sebti SM: Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene 2000, 19:5525-5533.
32. Hata A: TGFbeta signaling and cancer. Exp Cell Res 2001, 264:111-116.
33. Rooke HM and Crosier KE: The smad proteins and TGFbeta signalling: uncovering a pathway critical in cancer. Pathology 2001, 33:73-84.
34. Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F and Sun LZ: Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene 2002, 21:3541-3551.
35. Lei X, Bandyopadhyay A, Le T and Sun L: Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 2002, 21:7514-7523.
36. Dumont N and Arteaga CL: A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochem Biophys Res Commun 2003, 301:108-112.
37. Bruning A and Runnebaum IB: CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 2003, 10:198-205.
38. Ellenrieder V, Buck A and Gress TM: TGFbeta-regulated transcriptional mechanisms in cancer. Int J Gastrointest Cancer 2002, 31:61-69.
39. Ryu B and Kern SE: The Essential Similarity of TGFbeta and Activin Receptor Transcriptional Responses in Cancer Cells. Cancer Biol Ther 2003, 2:164-170.
40. Amendt C, Mann A, Schirmacher P and Blessing M: Resistance of keratinocytes to TGFbeta-mediated growth restriction and apoptosis induction accelerates re-epithelialization in skin wounds. J Cell Sci 2002, 115:2189-2198.
41. Khoo NK, Bechberger JF, Shepherd T, Bond SL, McCrae KR, Hamilton GS and Lala PK: SV40 Tag transformation of the normal invasive trophoblast results in a premalignant phenotype. I. Mechanisms responsible for hyperinvasiveness and resistance to anti-invasive action of TGFbeta. Int J Cancer 1998, 77:429-439.
42. Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL, Evans DB, Ayers D, Wathen K, Wu T, Robertson KD and Chiao PJ: Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002, 8:3628-3638.
43. Bartsch D, Barth P, Bastian D, Ramaswamy A, Gerdes B, Chaloupka B, Deiss Y, Simon B and Schudy A: Higher frequency of DPC4/ Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas. Cancer Lett 1999, 139:43-49.
44. Giehl K, Seidel B, Gierschik P, Adler G and Menke A: TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation. Oncogene 2000, 19:4531-4541.
45. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB and Sheppard D: The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999, 96:319-328.
46. Lu M, Munger JS, Steadele M, Busald C, Tellier M and Schnapp LM: Integrin alpha8beta1 mediates adhesion to LAP-TGFbeta1. J Cell Sci 2002, 115:4641-4648.
47. Ludbrook SB, Barry ST, Delves CJ and Horgan CM: The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem J 2003, 369:311-318.
48. Saharinen J, Hyytiainen M, Taipale J and Keski-Oja J: Latent transforming growth factor-beta binding proteins (LTBPs) - structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999, 10:99-117.
49. Munger JS, Harpel JG, Giancotti FG and Rifkin DB: Interactions between growth factors and integrins: latent forms of transforming growth factor-beta are ligands for the integrin alphavbeta1. Mol Biol Cell 1998, 9:2627-2638.
50. Saharinen J, Taipale J, Monni O and Keski-Oja J: Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J Biol Chem 1998, 273:18459-18469.
51. Yuan X, Downing AK, Knott V and Handford PA: Solution structure of the transforming growth factor beta-binding protein-like module, a domain associated with matrix fibrils. Embo J 1997, 16:6659-6666.
52. Yang Y, Dignam JD and Gentry LE: Role of carbohydrate structures in the binding of beta1-latency-associated peptide to ligands. Biochemistry 1997, 36:11923-11932.
53. Grainger DJ, Wakefield L, Bethell HW, Farndale RW and Metcalfe JC: Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1995, 1:932-937.
54. Annes JP, Munger JS and Rifkin DB: Making sense of latent TGF-beta activation. J Cell Sci 2003, 116:217-224.
55. Altmann CR, Chang C, Munoz-Sanjuan I, Bell E, Heke M, Rifkin DB and Brivanlou AH: The latent-TGFbeta-binding-protein-1 (LTBP-1) is expressed in the organizer and regulates nodal and activin signaling. Dev Biol 2002, 248:118-127.
56. Le M, Gohr CM and Rosenthal AK: Transglutaminase participates in the incorporation of latent TGFbeta into the extracellular matrix of aging articular chondrocytes. Connect Tissue Res 2001, 42:245-253.
57. Saika S, Miyamoto T, Tanaka T, Ishida I, Ohnishi Y and Ooshima A: Latent TGFbeta binding protein-1 and fibrillin-1 in human capsular opacification and in cultured lens epithelial cells. Br J Ophthalmol 2001, 85:1362-1366.
58. Linder S, Castanos-Velez E, von Rosen A and Biberfeld P: Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology 2001, 48:1321-1327.
59. Streit M, Schmidt R, Hilgenfeld RU, Thiel E and Kreuser ED: Adhesion receptors in malignant transformation and dissemination of gastrointestinal tumors. J Mol Med 1996, 74:253-268.
60. Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maier A, Kloppel G, Liebe S and Kreuser ED: Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas 1996, 12:248-259.
61. Weinel RJ, Rosendahl A, Pinschmidt E, Kisker O, Simon B and Santoso S: The alpha 6-integrin receptor in pancreatic carcinoma. Gastroenterology 1995, 108:523-532.
62. Weinel RJ, Rosendahl A, Neumann K, Chaloupka B, Erb D, Rothmund M and Santoso S: Expression and function of VLA-alpha 2, - alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. Int J Cancer 1992, 52:827-833.
63. Timar J, Chopra H, Rong X, Hatfield JS, Fligiel SE, Onoda JM, Taylor JD and Honn KV: Calcium channel blocker treatment of tumor cells induces alterations in the cytoskeleton, mobility of the integrin alpha IIb beta 3 and tumor-cell-induced platelet aggregation. J Cancer Res Clin Oncol 1992, 118:425-434.
64. Beck R, Nebe B, Guthoff R and Rychly J: Inhibition of lens epithelial cell adhesion by the calcium antagonist Mibefradil correlates with impaired integrin distribution and organization of the cytoskeleton. Graefes Arch Clin Exp Ophthalmol 2001, 239:452-458.
65. Schmidt C, Pommerenke H, Durr F, Nebe B and Rychly J: Mechanical stressing of integrin receptors induces enhanced tyrosine phosphorylation of cytoskeletally anchored proteins. J Biol Chem 1998, 273:5081-5085.
66. Pommerenke H, Schmidt C, Durr F, Nebe B, Luthen F, Muller P and Rychly J: The mode of mechanical integrin stressing controls intracellular signaling in osteoblasts. J Bone Miner Res 2002, 17:603-611.
67. Carethers JM and Pham TT: Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. In Vivo 2000, 14:13-20.
68. Therrien JP, Loignon M, Drouin R and Drobetsky EA: Ablation of p21waf1cip1 expression enhances the capacity of p53-deficient human tumor cells to repair UVB-induced DNA damage. Cancer Res 2001, 61:3781-3786.
69. Houle F, Rousseau S, Morrice N, Luc M, Mongrain S, Turner CE, Tanaka S, Moreau P and Huot J: Extracellular signal-regulated kinase mediates phosphorylation of tropomyosin-1 to promote cytoskeleton remodeling in response to oxidative stress: impact on membrane blebbing. Mol Biol Cell 2003, 14:1418-1432.
70. Fincham VJ, James M, Frame MC and Winder SJ: Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. Embo J 2000, 19:2911-2923.
71. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000, 2:249-256.
72. Achison M, Elton CM, Hargreaves PG, Knight CG, Barnes MJ and Farndale RW: Integrin-independent tyrosine phosphorylation of p125(fak) in human platelets stimulated by collagen. J Biol Chem 2001, 276:3167-3174.
73. Farre L, Casanova I, Guerrero S, Trias M, Capella G and Mangues R: Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model. Faseb J 2002, 16:975-982.
74. Liboi E, Di Francesco P, Gallinari P, Testa U, Rossi GB and Peschle C: TGF beta induces a sustained c-fos expression associated with stimulation or inhibition of cell growth in EL2 or NIH 3T3 fibroblasts. Biochem Biophys Res Commun 1988, 151:298-305.
75. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM and Massague J: Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990, 62:175-185.
76. Inagaki M, Moustakas A, Lin HY, Lodish HF and Carr BI: Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A 1993, 90:5359-5363.
77. Herrera RE, Makela TP and Weinberg RA: TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein. Mol Biol Cell 1996, 7:1335-1342.
78. Edens M and Leof EB: In vitro assays for measuring TGF-beta growth stimulation and inhibition. Methods Mol Biol 2000, 142:1-11.
79. Giancotti FG and Ruoslahti E: Integrin signaling. Science 1999, 285:1028-1032.
80. Huang W, Rudkin GH, Carlsen B, Ishida K, Ghasri P, Anvar B, Yamaguchi DT and Miller TA: Overexpression of BMP-2 modulates morphology, growth, and gene expression in osteoblastic cells. Exp Cell Res 2002, 274:226-234.
81. Wyatt LE, Chung CY, Carlsen B, Iida-Klein A, Rudkin GH, Ishida K, Yamaguchi DT and Miller TA: Bone morphogenetic protein-2 (BMP-2) and transforming growth factor-beta1 (TGF-beta1) alter connexin 43 phosphorylation in MC3T3-E1 Cells. BMC Cell Biol 2001, 2:14.
82. Zerath E, Holy X, Noel B, Malouvier A, Hott M and Marie PJ: Effects of BMP-2 on osteoblastic cells and on skeletal growth and bone formation in unloaded rats. Growth Horm IGF Res 1998, 8:141-149.
83. Mainiero F, Gismondi A, Soriani A, Cippitelli M, Palmieri G, Jacobelli J, Piccoli M, Frati L and Santoni A: Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon gamma production in human natural killer cells. J Exp Med 1998, 188:1267-1275.
84. Barberis L, Wary KK, Fiucci G, Liu F, Hirsch E, Brancaccio M, Altruda F, Tarone G and Giancotti FG: Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK. J Biol Chem 2000, 275:36532-36540.
85. Whitlock BB, Gardai S, Fadok V, Bratton D and Henson PM: Differential roles for alpha(M)beta(2) integrin clustering or activation in the control of apoptosis via regulation of akt and ERK survival mechanisms. J Cell Biol 2000, 151:1305-1320.
86. Aplin AE, Stewart SA, Assoian RK and Juliano RL: Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 2001, 153:273-282.
87. Sablina AA, Chumakov PM, Levine AJ and Kopnin BP: p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. Oncogene 2001, 20:899-909.
88. Brunton VG, Fincham VJ, McLean GW, Winder SJ, Paraskeva C, Marshall JF and Frame MC: The protrusive phase and full development of integrin-dependent adhesions in colon epithelial cells require FAK- and ERK-mediated actin spike formation: deregulation in cancer cells. Neoplasia 2001, 3:215-226.
89. Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ, Scott RJ, Baker MS, Macreadie IG and Agrez MV: Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene 2002, 21:1370-1380.
90. Weyts FA, Li YS, van Leeuwen J, Weinans H and Chien S: ERK activation and alpha v beta 3 integrin signaling through Shc recruitment in response to mechanical stimulation in human osteoblasts. J Cell Biochem 2002, 87:85-92.
91. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D and Korc M: Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999, 255:268-273.
92. Calonge MJ and Massague J: Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 1999, 274:33637-33643.
93. Inman GJ and Allday MJ: Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 2000, 81:1567-1578.
94. Lee S, Cho YS, Shim C, Kim J, Choi J, Oh S, Zhang W and Lee J: Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Int J Cancer 2001, 94:500-507.
95. Paterson IC, Davies M, Stone A, Huntley S, Smith E, Pring M, Eveson JW, Robinson CM, Parkinson EK and Prime SS: TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest. Oncogene 2002, 21:1616-1624.
96. Macias-Silva M, Li W, Leu JI, Crissey MA and Taub R: Up-regulated transcriptional repressors SnoN and Ski bind Smad proteins to antagonize transforming growth factor-beta signals during liver regeneration. J Biol Chem 2002, 277:28483-28490.
97. Berger DH, Feng XH, Yao J, Saha D, Beauchamp RD and Lin X: Resistance to transforming growth factor-beta occurs in the presence of normal Smad activation. Surgery 2002, 132:310-316.
98. Schwarte-Waldhoff I and Schmiegel W: Smad4 transcriptional pathways and angiogenesis. Int J Gastrointest Cancer 2002, 31:47-59.
99. Nicolas FJ and Hill CS: Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003, 22:3698-3711.
100. Stoika R, Yakymovych M, Souchelnytskyi S and Yakymovych I: Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Acta Biochim Pol 2003, 50:497-508.
101. Yamanaka I, Koizumi M, Baba T, Yamashita S, Suzuki T and Kudo R: Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells. Exp Cell Res 2003, 286:165-174.
102. Kabir-Salmani M, Shiokawa S, Akimoto Y, Sakai K, Nagamatsu S, Nakamura Y, Lotfi A, Kawakami H and Iwashita M: Alphavbeta3 integrin signaling pathway is involved in insulin-like growth factor I-stimulated human extravillous trophoblast cell migration. Endocrinology 2003, 144:1620-1630.
103. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, Horowitz JC, Day RM and Thomas PE: Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003, 278:12384-12389.
104. Smyth SS and Patterson C: Tiny dancers: the integrin-growth factor nexus in angiogenic signaling. J Cell Biol 2002, 158:17-21.
105. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D and Cheresh DA: Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002, 157:149-160.
106. Hermanto U, Zong CS, Li W and Wang LH: RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol 2002, 22:2345-2365.
107. Lee JW and Juliano RL: The alpha5beta1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells. Biochim Biophys Acta 2002, 1542:23-31.
108. Bhowmick NA, Zent R, Ghiassi M, McDonnell M and Moses HL: Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem 2001, 276:46707-46713.
109. Gleeson LM, Chakraborty C, McKinnon T and Lala PK: Insulin-like growth factor-binding protein 1 stimulates human trophoblast migration by signaling through alpha 5 beta 1 integrin via mitogen-activated protein Kinase pathway. J Clin Endocrinol Metab 2001, 86:2484-2493.
110. Lai CF, Feng X, Nishimura R, Teitelbaum SL, Avioli LV, Ross FP and Cheng SL: Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. J Biol Chem 2000, 275:36400-36406.
111. Renshaw MW, Price LS and Schwartz MA: Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J Cell Biol 1999, 147:611-618.
112. Skinner MA and Wildeman AG: beta(1) integrin binds the 16-kDa subunit of vacuolar H(+)-ATPase at a site important for human papillomavirus E5 and platelet-derived growth factor signaling. J Biol Chem 1999, 274:23119-23127.
113. Aplin AE and Juliano RL: Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J Cell Sci 1999, 112 ( Pt 5):695-706.
114. Gu J, Tamura M and Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol 1998, 143:1375-1383.
115. Zheng B and Clemmons DR: Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci U S A 1998, 95:11217-11222.
116. Gotoh A, Ritchie A, Takahira H and Broxmeyer HE: Thrombopoietin and erythropoietin activate inside-out signaling of integrin and enhance adhesion to immobilized fibronectin in human growth-factor-dependent hematopoietic cells. Ann Hematol 1997, 75:207-213.
117. Genersch E, Schuppan D and Lichtner RB: Signaling by epidermal growth factor differentially affects integrin-mediated adhesion of tumor cells to extracellular matrix proteins. J Mol Med 1996, 74:609-616.
118. Plopper GE, McNamee HP, Dike LE, Bojanowski K and Ingber DE: Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex. Mol Biol Cell 1995, 6:1349-1365.
119. Kraft S, Diefenbach B, Mehta R, Jonczyk A, Luckenbach GA and Goodman SL: Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J Biol Chem 1999, 274:1979-1985.
120. Hu DD, White CA, Panzer-Knodle S, Page JD, Nicholson N and Smith JW: A new model of dual interacting ligand binding sites on integrin alphaIIbbeta3. J Biol Chem 1999, 274:4633-4639.
121. Fujioka S, Sclabas GM, Schmidt C, Niu J, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003, 22:1365-1370.
122. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB and Chiao PJ: Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the antiepidermal growth factor antibody IMC-C225. J Gastrointest Surg 2003, 7:37-43; discussion 43.
123. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003, 9:346-354.
124. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ and Chiao PJ: The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 2002, 21:6510-6519.
125. Mineo C, Anderson RG and White MA: Physical association with ras enhances activation of membrane-bound raf (RafCAAX). J Biol Chem 1997, 272:10345-10348.